MX2019006066A - 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. - Google Patents

5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.

Info

Publication number
MX2019006066A
MX2019006066A MX2019006066A MX2019006066A MX2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A MX 2019006066 A MX2019006066 A MX 2019006066A
Authority
MX
Mexico
Prior art keywords
thiazolidine
dione
pyridin
ethoxy
hydroxyethyl
Prior art date
Application number
MX2019006066A
Other languages
English (en)
Inventor
Pilar Pizcueta Lalanza Maria
Martinell Pedemonte Marc
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Publication of MX2019006066A publication Critical patent/MX2019006066A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se relaciona con un método para tratar o prevenir la enfermedad del hígado graso no alcohólico, la esteatohepatitis no alcohólica, un trastorno granulomatoso crónico, un síndrome de ovario poliquístico, un carcinoma de tiroides, un trastorno autoinmune de tiroides, un adenoma hipofisario, aterosclerosis, hipertensión, una enfermedad de la piel, una inflamación y una enfermedad autoinmune, y una enfermedad respiratoria inflamatoria mediante la administración de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3- tiazolidin-2,4-diona a un paciente que lo necesita. La descripción también se relaciona con 5-[[4-[2-[5-(1-hidroxietil)pi ridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-diona para uso en una composición farmacéutica o en la fabricación de un medicamento para el tratamiento o la prevención de la enfermedad del hígado graso no alcohólico o la esteatohepatitis no alcohólica.
MX2019006066A 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. MX2019006066A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382584 2016-12-01
PCT/IB2017/057587 WO2018100557A1 (en) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
MX2019006066A true MX2019006066A (es) 2019-09-10

Family

ID=57517838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006066A MX2019006066A (es) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-t iazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.

Country Status (20)

Country Link
US (1) US11938122B2 (es)
EP (1) EP3548026B1 (es)
JP (1) JP7040798B2 (es)
KR (1) KR102595034B1 (es)
CN (1) CN110022877B (es)
AU (1) AU2017370003B2 (es)
BR (1) BR112019011334A2 (es)
CA (1) CA3044364A1 (es)
CY (1) CY1124116T1 (es)
DK (1) DK3548026T3 (es)
EA (1) EA201991304A1 (es)
ES (1) ES2867300T3 (es)
HR (1) HRP20210576T1 (es)
HU (1) HUE054346T2 (es)
LT (1) LT3548026T (es)
MX (1) MX2019006066A (es)
PL (1) PL3548026T3 (es)
PT (1) PT3548026T (es)
SI (1) SI3548026T1 (es)
WO (1) WO2018100557A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2867300T3 (es) 2016-12-01 2021-10-20 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-diona para tratamiento de enfermedad de hígado graso no alcohólico
JP7376934B2 (ja) 2018-06-06 2023-11-09 ミノリックス セラピューティクス エセ．エレ． ミトコンドリア性疾患の処置における使用のための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンおよびその塩
AU2021265345A1 (en) 2020-04-30 2022-12-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
CA2106967C (en) * 1991-04-11 2003-12-09 Takashi Sohda Thiazolidinedione derivatives, production and use thereof
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP2005514399A (ja) 2001-12-21 2005-05-19 スミスクライン ビーチャム コーポレーション ＰＰＡＲγアクチベーターの投薬法
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
RU2445957C2 (ru) 2006-03-16 2012-03-27 Метаболик Солюшнз Девелопмент Компани Аналоги тиазолидиндиона
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
WO2013040419A1 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
DK3388064T3 (da) 2014-04-02 2021-04-19 Minoryx Therapeutics S L 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet
ES2867300T3 (es) 2016-12-01 2021-10-20 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-diona para tratamiento de enfermedad de hígado graso no alcohólico

Also Published As

Publication number Publication date
CN110022877B (zh) 2023-06-23
DK3548026T3 (da) 2021-04-19
HUE054346T2 (hu) 2021-08-30
JP7040798B2 (ja) 2022-03-23
EA201991304A1 (ru) 2019-12-30
CY1124116T1 (el) 2022-05-27
US20200093812A1 (en) 2020-03-26
ES2867300T3 (es) 2021-10-20
EP3548026B1 (en) 2021-01-20
CN110022877A (zh) 2019-07-16
CA3044364A1 (en) 2018-06-07
KR102595034B1 (ko) 2023-10-26
PT3548026T (pt) 2021-04-22
JP2020500868A (ja) 2020-01-16
BR112019011334A2 (pt) 2019-10-15
EP3548026A1 (en) 2019-10-09
PL3548026T3 (pl) 2021-08-23
AU2017370003A1 (en) 2019-06-06
AU2017370003B2 (en) 2023-04-13
WO2018100557A1 (en) 2018-06-07
SI3548026T1 (sl) 2021-07-30
US11938122B2 (en) 2024-03-26
LT3548026T (lt) 2021-05-25
HRP20210576T1 (hr) 2021-05-28
KR20190086766A (ko) 2019-07-23

Similar Documents

Publication Publication Date Title
CY1124116T1 (el) 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος
PH12019500056A1 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
MY180160A (en) A novel composition for nonalcoholic fatty liver disease (nafld)
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
NZ602125A (en) Uses of dgat1 inhibitors
MX2013009842A (es) Composicion que comprende receptor gamma activado por proliferador de peroxisoma.
RU2015139758A (ru) Хиназолины в качестве ингибиторов киназы
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
JP6640840B2 (ja) 線維症を処置するための方法及び医薬組成物
MX2020013182A (es) Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.
SG11202012045UA (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
MX2018006921A (es) Métodos y composiciones para el tratamiento de úlceras gástricas.
WO2014004664A3 (en) Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
MX2022013021A (es) Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
EA201692515A1 (ru) Новая фармацевтическая композиция на основе софосбувира и рибавирина
EP2598141A4 (en) N-HYDROXYURED PHENYLALKYL FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH LEUKOTRIENES
NZ597864A (en) Methods and compositions for treating leukemia
Aydin Peginterferon-α-2b
MX2016002856A (es) Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon.
PH12014501088A1 (en) Pharmaceutical composition for preventing or treating hyperlipidemia
Marutaka Gimeracil/oteracil/tegafur/warfarin interaction